Less invasive beractant administration in preterm infants: a pilot study by Ramos-Navarro, Cristina et al.
Less invasive beractant administration in preterm
infants: a pilot study
Cristina Ramos-Navarro*, Manuel Sa´nchez-Luna, Susana Zeballos-Sarrato, Noelia Gonza´lez-Pacheco
Complutense University, Gregorio Maran˜on University Hospital, Biomedical Research Institute Gregorio Maran˜on, Neonatology Division, Madrid/Spain.
OBJECTIVES: The aims of this study were to assess the efficacy and feasibility of a new, less invasive surfactant
administration technique for beractant replacement using a specifically designed cannula in preterm infants
born at o32 weeks of gestation and to compare short- and long-term outcomes between this approach and
standard treatment, consisting of intubation, administration of surfactant and early extubation to nasal
continuous positive airway pressure.
METHOD: This was a single-center, prospective, open-label, non-randomized, controlled pilot study with an
experimental cohort of 30 patients treated with less invasive surfactant administration and a retrospective
control group comprising the 30 patients most recently treated with the standard approach. Beractant (4 ml/kg)
was administered as an exogenous surfactant in both groups if patients on nasal continuous positive airway
pressure during the first three days of life were in need of more than 30% FiO2. Clinicaltrials.gov: NCT02611284.
RESULTS: In the group with less invasive surfactant administration, beractant was successfully administered in all
patients. Thirteen patients (43.3%) in the group with less invasive surfactant administration required invasive
mechanical ventilation for more than 1 hour during the first 3 days of life, compared with 22 (73%) in the
control group (po0.036). The rate of requiring invasive mechanical ventilation for more than 48 hours was
similar between the infants in the two groups (46% vs. 40%, respectively). There were no differences in other
outcomes.
CONCLUSION: The administration of beractant (4 ml/kg) using a less invasive surfactant administration
technique with a specifically designed cannula for administration is feasible. Moreover, early invasive
mechanical ventilation exposure is significantly reduced by this method compared with the strategy involving
intubation, surfactant administration and early extubation.
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’ INTRODUCTION
Over the last few years, there has been a trend of less invasive
respiratory management among preterm infants due to the
association between invasive mechanical ventilation (iMV) and
bronchopulmonary dysplasia (BPD) development. Currently,
applying nasal continuous positive airway pressure (nCPAP)
from birth combined with early surfactant administration to
avoid iMV is a standard of care in preterm infants (1,2).
Until recently, exogenous surfactant administration has
required intubation and positive pressure ventilation (PPV)
during instillation. This implies that certain infants managed
with nCPAP have had to be intubated only for the purpose of
administering exogenous surfactant. Early surfactant treatment
improves respiratory outcomes in patients with respiratory
distress syndrome (RDS) (3), but as endotracheal intubation can
be hazardous (4,5) and iMVexposure can induce lung injuries (6),
the potential benefit of surfactant treatment is counterbalanced
by ventilator-induced damage. To reduce iMV exposure, early
extubation after surfactant administration (intubation-surfactant-
extubation, or INSURE) has been proposed, but iMV is still
required during surfactant administration and in certain cases
(7-19%), extubation cannot be performed after treatment (7,8). To
prevent endotracheal intubation and iMV during and after
surfactant administration, the decision to administer exogenous
surfactant can occasionally be delayed.
To prevent intubation but ensure early surfactant admin-
istration, several techniques for ‘‘less invasive surfactant
administration’’ (LISA) have been described recently. In these
techniques, the exogenous surfactant can be delivered with-
out tracheal intubation, instead using nasopharyngeal instilla-
tion (9), laryngeal mask placement (10) or aerosolization (11).DOI: 10.6061/clinics/2016(03)02
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However, none of these methods is currently ready for
application. Another more widely used method is to use a
thin catheter while the infant breathes spontaneously, sup-
ported with nCPAP. A thin (5- to 6-gauge) feeding tube has
been used, with the disadvantage of needing to use a Magill
forceps for its placement (12-15).
To address this problem, certain researchers have modified
the technique by using a more stable vascular catheter
(16-18). This method has been analyzed in comparative
studies. A recent review that included 2,361 treated neonates
(19) concluded that exogenous surfactant administration via
a thin catheter might be an efficacious and safe method, with
a potential reduction in the need for mechanical ventilation
within the first 72 hours of birth compared with standard
care. In the present study, to reduce invasiveness and ensure
security, we tested a specifically designed surfactant replace-
ment tube that is rigid enough to be placed in the trachea
without the need to employ any forceps and that has a blunt
tip to avoid any possible damage during placement. Beractant
(Survantas) is a natural surfactant not documented for use in
the LISA technique; the high-volume dose needed (4 ml/kg)
is probably a concern limiting its use. The particular aims of
this study were to assess the feasibility and effectiveness of
100 mg/kg (4 ml/kg) beractant administered by LISA using a
specifically designed surfactant replacement tube and to com-
pare the short- and long-term respiratory outcomes between
patients treated with this approach and a cohort of similar
historical controls.
’ MATERIALS AND METHODS
This single-center, prospective, open-label, non-randomized,
historically controlled pilot study involved an experimental co-
hort of 30 patients treated with a new LISA technique and a
retrospective control group comprising the 30 patients most
recently treated with surfactant using the standard method
who met the inclusion criteria. Preterm infants born at o32
weeks of gestation (WG) and breathing spontaneously on
nCPAP during the first three days of life who met the exoge-
nous surfactant administration criteria (Table 1) were eligible to
enroll in the study. Infants who met the intubation criteria
(Table 1) at the moment of surfactant administration were
excluded from both groups.
Treatment cohort (LISA)
All preterm infants born at o32 WG between October
2013 and November 2014 who met the inclusion criteria were
managed using the new LISA technique and enrolled in
the study group. All infants were supported with nCPAP
(5-8 cmH2O) while breathing spontaneously during instilla-
tion, delivered by an Infant Flow Drivers device (Care
Fusion, San Diego, CA, USA) via short bi-nasal prongs. All
preterm infants were properly positioned by a second
attending person, who contained the infant and facilitated
tucking during the procedure. The use of oral sucrose or
breast milk 2 minutes before the procedure was encouraged
to minimize the need for sedatives and opioids, but this
use was allowed at the discretion of the attending neo-
natologist. A 5-gauge French, gamma-sterilized, multi-access
catheter specifically designed (Figure 1) to deliver surfactants
in neonates/pediatric patients (KimVent Trach Care Technol-
ogys, Kimberly-Clark Health Care, West Malling, Kent,
United Kingdom) was placed 1-2 cm below the vocal cords
by direct laryngoscopy, without the use of a Magill forceps.
Correct positioning of the catheter tip was ensured based on
the numeric marks on the catheter. Beractant was used as the
exogenous natural surfactant, (100 mg/kg; 4 ml/kg) and was
administered in two aliquots over 1-3 minutes. All infants
were monitored by continuous electrocardiogram (EKG) and
peripheral pulse oximetry. Positive pressure inflation (PPI)
was given using a mask and bag only if the infant was apneic
or if bradycardia developed, despite the interruption of the
procedure. During surfactant instillation, gastric aspiration
was performed through a standard nasogastric feeding tube
to discount any misplacement of the surfactant catheter. The
surfactant administration catheter was removed after surfac-
tant instillation and nCPAP support was maintained, with
FiO2 adjusted for 90-95% target SpO2. A second dose of
surfactant was administered during the first 3 days of life if
more than 40% FiO2 was needed while on nCPAP with at least
6 cmH2O pressure. All infants received prophylactic intrave-
nous caffeine citrate (loading dose of 20 mg/kg, followed by
5 mg/kg/d) during the first 8 hours of life. LISA failure was
considered when intubation during the first three days of life
was required.
Historical cohort (standard treatment)
The control group was collected from the period immedi-
ately before the study’s initiation (from June 2012 to
September 2013). This cohort comprised preterm infants
born at o32 WG who met the inclusion criteria. Standard
management was performed using beractant (4 ml/kg) after
endotracheal intubation. A multi-access catheter designed to
deliver surfactants in neonates/pediatric patients (KimVent
Trach Care Technologys, Kimberly-Clark Health Care, West
Malling, Kent, United Kingdom) was pre-connected to the
Table 1 - Surfactant administration and intubation criteria in
preterm infants on nCPAP PEEP X 6cmH2O) (control and less
invasive surfactant administration groups).
Surfactant Administration Criteria Intubation Criteria
FiO2450% (SpO2 90-95%)
First dose: FiO2430% (SpO2 90-95%)
Second dose: FiO2440% (SpO2 90-95%)
Apnea episodes (44/h or more
than 1 requiring PPV)
Respiratory acidosis, pCO2
465 mmHg and pHo7.20 in
arterial or capillary samples
PEEP: Positive end-expiratory pressure.
Figure 1 - A 5-gauge French, gamma-sterilized, multi-access
catheter specifically designed to deliver surfactants in neonates/
pediatric patients.
129
CLINICS 2016;71(3):128-134 LISA in preterm infants
Ramos-Navarro C et al.
endotracheal tube and used for surfactant administration
without having to disconnect the ventilator. While surfactant
was administered, all infants were connected to pressure
support ventilation (PSV) combined with volume guarantee
(VG), Dräger VN500 ventilator (Dräger Medical, Lübeck,
Germany). A tidal volume of 4 ml/kg was initially employed.
After surfactant administration, all infants were to be
extubated, in accordance with our institutional extubation
guidelines, if FiO2o0.35, for a target SpO2 of490%, and if a
consistent respiratory effort was present. Extubation was
supported with nCPAP in all patients.
Outcomes
The primary endpoint was the percentage of patients who
required more than 1 hour of mechanical ventilation during the
first three days of life. Secondary endpoints were the need for
iMV at any time, its duration and the requirement of a second
dose of surfactant. Other outcomes collected were the incidence
of patent ductus arteriosus (PDA), BPD (moderate to severe
according to the physiological definition (17)) or air leaks.
To assess the feasibility of the technique, the number of
attempts to catheterize the trachea was recorded, as was the
number of bradycardia episodes (o100 bpm) needing PPI
during instillation, the number of surfactant reflux cases and
any misplacement of the catheter. The effectiveness of surfactant
administration was assessed in both groups based on reduction
of the FiO2 requirement by more than 20%.
Statistical analysis
A convenience sample size of 30 patients in each group
was selected for this pilot study.
Variables of interest are expressed as percentages, as means
(standard deviations) for normally distributed continuous
variables and as medians (ranges) for non-normally distributed
variables according to the Kolmogorov-Smirnov test. Fisher’s
exact test (two-tailed) or the Mann-Whitney’s U test was used to
establish baseline differences between the infants in the LISA
and control cohorts. Additionally, logistic regression analysis
was used to investigate the association between the LISA and
standard treatment procedures and the need for mechanical
ventilation. These analyses were adjusted for the effects of
gestational age (GA) and the Critical Risk Index for Babies
(CRIB) score. Selected clinical variables were compared between
LISA success and LISA failure through a univariate comparison.
A p value ofo0.05 was considered statistically significant. The
data were analyzed using SPSS package version 19.0 (SPSS,
Chicago, IL, USA) for Windows.
’ ETHICS
The Institutional Ethics Committee approved the study
and written consent was also obtained for the prospective
LISA cohort.
’ RESULTS
From October 2013 to November 2014, 98 preterm infants
were born at o32 WG at our level III institution. Overall,
65.3% of infants (n=64) could be managed without intuba-
tion at birth. A total of 23 of the patients on nCPAP from
birth met the surfactant administration criteria and were
included in the study group. In addition, seven patients who
were intubated in the delivery room for stabilization and
extubated after surfactant treatment met the inclusion criteria
for their second dose of surfactant, so a total of 30 patients
were included in the study group.
From June 2012 to September 2013 (the control period), 148
infants were born at o32 WG, and 96 (64.8%) did not need
intubation at birth. Of these 96 spontaneously breathing
patients supported with nCPAP, 35 met the inclusion criteria.
We selected the 30 patients born immediately before to form
the control group.
There were no differences between the two groups in
terms of baseline characteristics or prenatal risk factors,
except for the Clinical Risk Index for Babies (CRIB) Score,
which was significantly higher in the LISA group, indicating
higher initial severity in clinical status (Table 2).
Beractant (4 ml/kg) was administered in both groups.
The LISA technique was feasible in all of the patients and
was executed by a senior neonatologist in 23 patients and by
a neonatology fellow in 7 patients. The catheter was properly
inserted in all patients and the surfactant was administered
without any significant incident. None of the patients in the
LISA group required intubation for surfactant administra-
tion. For all patients who did need intubation, this was
performed more than 1 hour after the procedure. The
surfactant was specifically administered in two divided
aliquots over 1-2 minutes and all infants exhibited hemody-
namic stability during and after the procedure. A FiO2
reduction of more than 20% during the first hour after
surfactant administration was observed in 73.3% of the LISA
group, compared with 86.6% in the control group (p40.05).
Slight reflux of the surfactant was observed in 2 patients
(6.7%) in the LISA group, and an adequate response to
surfactant was noted in both groups. No sedatives were
given in the LISA group. In the control group, analgesics
Table 2 - Baseline characteristics of the study population.
LISA N=30 STANDARD TREATMENT N=30 p (95% CI)
Gestational age (weeks), mean 28.4 29.1 0.15
Np29 weeks 17 14
N429 weeks 13 16
Birth weight (grams), mean 1058 1232 0.26
Male gender, n(%) 12(40) 18(60) 0.12
Prenatal steroids, n(%) 22(73) 21(70) 0.42
C-section, n(%) 24(80) 22(73.3) 0.54
Intubation at delivery, n(%) 7(23.3) 0 0.05
CRIB score, mean;SD 4;3.08 1.9;2.09 0.003
Age at procedure (hours), mean 11.4 11 0.76
First dose of surfactant, n(%) 23(76.7) 30(100) 0.005
FiO2 prior to surfactant administration, % 42 40 0.59
C-section: Caesarean section.
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(morphine or fentanyl) were administered in 9 infants (30%).
The failure rate was 77.7% in the control group in which
analgesics were administered compared with 62% in the
control group in which analgesics were not used (p40.05).
Primary outcome
Thirteen patients (43.3%) in the LISA group required iMV
for more than one hour during the first three days of life,
compared with 22 (73%) in the standard treatment control
group (OR: 3.596; 95% CI 1.216-10.638; p=0.02). After
adjustment for GA and the CRIB score, the benefit of the
LISA technique was even more evident (OR 6.484; 95% CI
1.689-24.893; p=0.006).
Secondary outcomes
Secondary outcomes are shown in Table 3. There were no
statistically significant differences in the need for a second
dose of surfactant, the duration of mechanical ventilation, or
the PDA or BPD incidence rate. The rate requiring iMV for
more than 48 hours was similar between the infants in the
two groups (46% vs. 40%, respectively) (Figure 2). The risk
factors associated with LISA failure were a lower GA and
a lack of reduction in FiO2 after surfactant administration
(RR: 3.208; 95% CI 1.545-6.664; p=0.012) (Table 4). Patients
with LISA failure had longer endotracheal mechanical
ventilation than the group with LISA success did (median
number of days: 196.46 vs. 9.18, respectively; p=0.04).
’ DISCUSSION
The LISA technique using a specifically designed catheter
for 4 ml/kg beractant administration is feasible and safe and
decreases early iMV exposure in comparison with standard
treatment. To our knowledge, this is the first study of a LISA
technique using beractant as the exogenous surfactant and a
specifically designed catheter for surfactant administration.
Currently, avoidance of intubation is one of the main targets
in respiratory management among preterm infants, especially
in the first few hours of life, due to the association between
ventilator-induced lung injury and BPD (6). In addition, early
surfactant administration improves respiratory outcomes com-
pared with later use in patients with RDS (1,20). The decision to
administer surfactant in a patient with spontaneous breathing
is difficult and is occasionally delayed to avoid intubation and
invasive ventilation through the endotracheal tube. Even with
the INSURE method, a brief period of PPV is required and at
times, extubation cannot be rapidly performed (7,8). In the
Table 3 - Postnatal respiratory management of less invasive surfactant administration and INSURE groups.
LISA N=30 STANDARD TREATMENT N=30 p (95% CI)
Gestational age (weeks), median 28.4 29.1 0.15
Age at procedure (hours), mean(SD) 11.4(14.7) 11(14.7) 0.76
2 or more attempts, n(%) 5(16.7) -
Bradycardia (410 seg), n(%) 3(10) -
Surfactant reflux, n(%) 2(6.7) -
FiO2 before procedure, % 42 40 0.58
FiO2 reduction (420%), n(%) 22(73.3) 26(86.6) 0.08
Second dose of surfactant, n(%) 10(33.3) 9(30) 0.39
Pneumothorax, n(%) 2(6.7)* 1(3.3) 0.55
iMV 41 hour during first 3 days, n(%) 13(43) 22(73) 0.036
Total iMV (hours) 84.12 82.22 0.37
PDA, n(%) 11(36.7) 12(40) 0.79
Death or BPD (II-III), n(%) 8(26.6) 9(30) 0.61
Pharmacological analgesics, n(%) 0(0%) 9(30%) o0.05
*previously.
LISA: less invasive surfactant administration.
BPD: bronchopulmonary dysplasia; iMV: invasive mechanical ventilation; PDA: patent ductus arteriosus; PPI: positive pressure inflations; SD: standard
deviation.
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Figure 2 - Patients who needed intubation and invasive mechanical ventilation after less invasive surfactant administration or standard
treatment.
131
CLINICS 2016;71(3):128-134 LISA in preterm infants
Ramos-Navarro C et al.
present study, 73% of infants were exposed to iMV for more
than 1 hour after surfactant treatment in the control group.
Possible reasons for prolonged ventilation were the use of
analgesic with impairment in respiratory drive and a high
ventilator requirement after surfactant administration.
A current controversy surrounding this issue relates to the
use of sedatives and analgesics. One of the main reasons for
INSURE failure in many reports is apnea or insufficient
respiratory drive related to sedative use in many cases (21).
In fact, there is insufficient safety evidence to recommend a
drug and dose to be used in preterm infants during the
intubation procedure, particularly if the respiratory drive
must be preserved (22,23). The AMV trial (19) evidenced a
high risk of non-invasive surfactant failure in those infants in
whom sedation was administered (60% vs. 22%).
The use of pharmacological analgesics was allowed in both
groups in the present study, at the recommendation of the
attending neonatologist. However, for LISA treatment, specific
non-pharmacological measures were established to reduce the
need for sedatives. Major concern about the need for a
preserved respiratory drive, the positive effect of contention
and sucrose or breast milk (22) and the performance of this
technique by a senior neonatologist probably contributed to the
lack of use of sedatives in the LISA group, in contrast to the 30%
analgesic use in the control group. Even though apnea due to
analgesic use can contribute to an increased rate of iMV after
surfactant administration, we did not find significant differences
in the rate of iMVover more than 1 hour in the control group in
which analgesics were administered compared with the control
group in which analgesics were not used (77.7% vs. 62%,
respectively; p40.05). The LISA technique was performed in
only one attempt in 83.3% of cases. We believe that by
simplifying the technique, it can be performed easily, with a
very short laryngoscopy time; as a result, the use of analgesics
or sedation will not be necessary. Properly preventing sedative
use ensures the respiratory drive and also avoids the drop in
blood pressure and impairment of cerebral perfusion that have
been observed in preterm infants after sedative use (20-22). This
lack of analgesic use has been reported in several previously
published trials of LISA techniques (18,24-26).
The use of a specifically designed tube for surfactant
administration, one that is rigid enough to prevent the use of
forceps but that has a soft tip to prevent cord damage, made
the technique presented here easy and safe. Despite the
increased amount of beractant administered (4 ml/kg)
compared with other surfactant concentrations, it was well
tolerated and patients did not experience adverse effects. The
rates of surfactant reflux and bradycardia during instillation
(6.7% and 10%, respectively) in this study were similar to
those in other reports (20-40%) (16,19,23). However, a slight
drop (4100 bpm) in heart rate was more frequently
observed (30%), which was resolved by transient interrup-
tion of the procedure until resolution. To our knowledge, no
other studies have examined the use of beractant via a LISA
technique. The AMV trial (19) included 14 patients in whom
beractant was administered by a less invasive technique, but
no specific details of the procedure were reported.
Regarding surfactant administration effectiveness (more than
20% FiO2 reduction), no differences were found between
the groups (p=0.08). All infants not responding to surfactant
administration by LISA required iMV. In this group, a second
dose of surfactant was administered in 62.2% of cases (n=5),
with one administered by LISA and the others administered
after intubation. Once again, FiO2 reduction was not
observed. The total rate of requiring a second dose of
surfactant was similar between the infants in the two groups
(33.3% in the LISA group and 30% in the control group). This
finding was in contrast to the observation by Aguar et al. (24)
that the non-invasive surfactant group received a second
dose of surfactant at a significantly higher frequency
compared with the INSURE group. This fact supported the
researchers’ hypothesis that attributes intergroup differences
to a higher dose of surfactant applied in the INSURE group
(200 mg/kg) compared with the less invasive group (100
mg/kg), rather than being caused by the technique itself. In
contrast, in the present study, 100 mg/kg was administered in
both groups. A second dose was administered by the LISA
technique in 3 patients, one of whom did not require iMV.
Patients who needed intubation after LISA required pro-
longed ventilation, with a duration of more than 48 hours in
all cases. This rate (46%) was similar to that for the standard
method (40%) (Figure 2). No significant differences between
the groups were found for the other outcomes (Table 3). It
seems that by changing the technique, we can avoid unnec-
essary early intubations for surfactant treatment but that more
severe ill infants will still require mechanical ventilation.
The benefit of surfactant administration by this technique
is the avoidance of the use of unnecessary iMV around
surfactant administration, which can trigger an inflammatory
response in the lung and systemic circulation (6,27). This systemic
repercussion could explain the positive effect of LISA on survival,
without major complications, found in a recently published
Table 4 - Comparison of variables between the less invasive surfactant administration success and failure groups.
LISA Failure N=13 LISA Success N=17 p (95% CI)
Gestational age (weeks), mean(SD) 27.4(1.61) 29.1(2.02) 0.02
Birth weight (grams), mean(SD) 992(387) 1108 (397) 0.263
Prenatal corticosteroids, n(%) 9(69.2) 13(76.5) 0.691
Intubation at delivery, n(%) 30.8 17.6 0.4
Age at procedure (hours), mean(SD) 8.4(9.6) 13.7(17.7) 0.7
FiO2 before procedure, mean(SD) 4.6(37.6) 21.6(46) 0.5
FiO2 reduction after surfactant (420%), n(%) 6(46.2) 16(94.1) 0.003
PPI during instillation, n(%) 2(15.4) 1(5.9) 0.39
PDA, % 46 29.4 0.3
Total iMV (hours), mean(SD) 196.46(244) 9.18(18.7) 0.04
Pneumothorax, n(%) 2(15.4) 0 0.09
BPD (II-III), % 30.8 25.6 0.907
LISA: less invasive surfactant administration.
BPD: bronchopulmonary dysplasia; iMV: invasive mechanical ventilation; PPI: positive pressure inflations; SD: standard deviation.
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randomized controlled trial by Kribs et al. (28). Additionally, iMV
during surfactant administration has been shown to reduce the
effect of the surfactant administered (29,30), contributing to
impaired respiratory evolution. The LISA technique allows early
surfactant administration without the fear of unnecessary iMV
exposure and spontaneous breathing during LISA may contri-
bute to a better distribution of surfactant.
In the present study, no significant difference was found in
the death or BPD (II-III) rate between the LISA group (26.6%)
and the control group (30%) (Table 3). A recent review of
2,630 patients found no statistically significant reduction in
BPD with surfactant administration via a thin catheter when
compared with INSURE or standard care (16,30).
In our study, all BPD patients in the LISA group had
moderate BPD (type II). There were 2 infants with severe
BPD in the control group. Even though no difference in
oxygen dependency was found at 36 WG, long-term follow-
up with an appropriate sample size is needed to assess any
possible beneficial effects of avoiding early intubations using
this technique on long-term lung function.
Based on the variables included in the univariate com-
parison between the LISA success and failure groups, the
risk factors associated with LISA failure were a lower GA
and a lack of reduction in FiO2 (Table 4).
Limitations
In this feasibility pilot study, the prospective study group was
compared with a historical control group. There was temporal
bias caused by the evolution of medical practice and technology,
although this bias was reduced because the control group
consisted of immediately before born preterm infants that met
the same surfactant administration criteria as LISA group. The
reasons for prolonged iMV after standard treatment could not
be properly collected in certain patients. Moreover, due to the
low number of patients included, the study was not powered to
examine the BPD outcome.
The LISA technique using a KimVent catheter for 4 ml/kg
beractant administration is feasible and safe and reduces iMV
exposure in the first 3 days of life compared with the previously
established standard method. There are no differences in other
outcomes. The risk factors associated with LISA failure were a
lower GA and a lack of reduction in FiO2 after surfactant
administration. LISA failure indicates more severe RDS that
requires prolonged mechanical ventilation.
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